Onkologie. 2010:4(2):84-88

News in treatment of prostate cancer-targeted therapy of hormone-refractory prostate cancer

Jana Katolická
Onkologicko-chirurgické oddělení, Fakultní nemocnice u svaté Anny, Brno
Lékařská fakulta MU, Brno

Prostate cancer is one of the leading causes of cancer related death in men, and remains incurable in the metastatic setting. Despote

the initial response to androgen deprivation, the disease gradually progresses to a hormone-refractory state due to cumulative genetic

alterations in tumour cells. Docetaxel represents the first chemotherapeutic agent with small survival benefit for metastatic hormonerefractory

prostate cancer (HRCP).In an attempt to improve survival benefit, several novel drugs targeting specific pathway involved

in cel proliferation, angiogenesis, apoptosis are currently under investigation either as single agents or in combination with cytotoxic

drugs. Clinical trials evaluate the inhibition of prostate cancer cells growth by vitamin D with cytotoxic therapy. Angiogenesis inhibitors

as well as epidermal growth factor receptor blockage are also under clinical investigation in several combinations.

Keywords: hormone-refractory prostate cancer, chemotherapy, targeted therapy

Published: May 1, 2010  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Katolická J. News in treatment of prostate cancer-targeted therapy of hormone-refractory prostate cancer. Onkologie. 2010;4(2):84-88.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. American cancer society: prostate cancer statistics. http://www.cancer.net/prostate.
    2. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednione for advanced refractory prostate cancer. New Engl J Med 2004; 351: 1513-1520. Go to original source... Go to PubMed...
    3. Tannock IF, de Wit R Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. New Engl J med 2004; 351: 1502-1512. Go to original source... Go to PubMed...
    4. Nakabayashi M, Ling J, Xie W, Regan MM, Oh WK. Response to vinorelbin with or without estramustine as second-line chemotherapy in patients with hormone-refractory prostate cancer. Cancer J 2007; 13: 125-129. Go to original source... Go to PubMed...
    5. Sternberg CN, Petrylak D, Witjes F, et al.Satraplatin (S) demonstrates significant clinical benefits for the treatment of patients with HRCP: results of a randomized phase III trial. J Clin Oncol 2007; 25(185) [abstr 5019]. Go to original source... Go to PubMed...
    6. Stavridi F, et al. Targeted therapeutic approaches for hormone-refractory prostate cancer. Cancer Treat Rev (2010)doi: 10.1016/j.ctrv.2009.06.001. Go to original source... Go to PubMed...
    7. George DJ, Halabi S, Shepard TF, et al. Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemie Group B 9480. Clin Cancer Res 2001; 7: 1932-1936.
    8. Picus J, Halabi S, Rini B, et al. The use o bevacizumab (B) with docetaxel (D) and estramustin (E) in hormone refractory prostate cancer (HRCP): initial results of CALGB 90006. Proc Am Soc Clin Oncol 2003; 22. [abstr 1578].
    9. Dahut WL, Gulley JL, Arlen PM, et al. Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. J Clin Oncol 2004; 22: 2532-2539. Go to original source... Go to PubMed...
    10. Beer TM, Ryan CW, Venner PM, et al. Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT investigators. J Clin Oncol 2007; 25: 669-674. Go to original source... Go to PubMed...
    11. Nelson JB, Hedican SP, Georgie DJ, et al. Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat Med 1995; 52: 944-949. Go to original source... Go to PubMed...
    12. Carducci MA, Padley RJ, Breul J, et al. Effect of endothelin-A receptor blockade with atrasetran on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial. J Clin Oncol 2003; 21: 679-689. Go to original source... Go to PubMed...
    13. Carducci MA, Saad F, Abrahamsson PA, et al. A phase 3 randomized controlled trial of the efficacy and safety of atrasetran in men with metastatic hormone-refractory prostate cancer. Cancer 2007; 110: 1959-1966. Go to original source... Go to PubMed...
    14. Sternberg CN, Dumez H, Van Poppel H, et al. Multicenter randomized EORTC trial 30021 of doceaxel + oblimersen and docetaxel in patients (pts) with hormone refractory prostate cancer (HRCP). Proc ASCO Prostate Cancer Symp 2007 [abstr 144].
    15. Chi KN, Eisenhauer E, Fazli L, et al. A phase I. pharmacokinetic and pharmakodynamic study of OGX -011, a 2-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer J Natl Cancer Inst 2005; 97: 1287-1296. Go to original source... Go to PubMed...
    16. Chi KN, Hotte SJ, Yu E, et al. A randomized phase II. study of OGX-011in combination with docetaxel and prednison or docetaxel and prednisone alone in patients with metstatic hormone refraktory prostate cancer (HRCP). J Clin Oncol 2007; 25(June 20 suppl). [abstr 5069]. Go to original source...
    17. Saad FS, Hotte SJ, North SA, et al. A pVhase II study randomized study of custirsen (OGX-011) combination therapy in patients with poor-risk hormone refractory prostate cancer (HRCP) who relapsed on or within six month of 1stline docetaxel therapy. J Clin Oncol 2008; 26(May 20 suppl). [abstr 5052]. Go to original source...
    18. Mathew P, Thall PF, Johnson MM, et al. Preliminary results of a randomized placebo-controlled double-blind trial of weekly docetaxel combined with imatinib in men with metastatic androgen-independent prostate cance (AIPC) and bone metastatases (BM). J Clin Oncol 2006; 24[abstr 4562]. Go to original source...
    19. Canil CM, Moore MJ, Winquist E, at al. Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: a trial of the National Cancer Institute of CanadaClinical Trials Group. J Clin Oncol 2005; 23: 455-460. Go to original source... Go to PubMed...
    20. Sonpavde G, Hutson TE, Berry WR, Boehm KA, Asmar L. Phase II trial of sunitinib for the therapy of progressive metastatic castration-refractory prostate cancer after previous docetaxel chemotherapy. Clin Genitourin Cancer 2008; 6(2): 134-137. Go to original source... Go to PubMed...
    21. Attard G, Reid AH, Yap TA, et al. Phase I flinkal trial of selective inhibitor of CYP17, abiraterone acetáte, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol 2008; 26(28): 4563-4571. Go to original source... Go to PubMed...
    22. Small EJ, Schellhammer PF, Gitano CS, et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J clin Oncol 2006; 24: 3089-3094. Go to original source... Go to PubMed...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.